TipRanks
Silence Therapeutics (DE:XRP2)
FRANKFURT:XRP2
Germany Market
XRP2
Silence Therapeutics
RESEARCH TOOLSreports

Silence Therapeutics (XRP2) Stock Forecast & Price Target

37 Followers
See the Price Targets and Ratings of:

XRP2 Analyst Ratings

Hold
6Ratings
Hold
1 Buy
4 Hold
1 Sell
Based on 6 analysts giving stock ratings to
Silence
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

XRP2 Stock 12 Month Forecast

Average Price Target

€17.10
▲(50.03% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Silence Therapeutics in the last 3 months. The average price target is €17.10 with a high forecast of €28.50 and a low forecast of €3.56. The average price target represents a 50.03% change from the last price of €11.40.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","29":"€29","8.75":"€8.75","15.5":"€15.5","22.25":"€22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28.50495104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€28.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.102970623999997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€17.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.56311888,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.56</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8.75,15.5,22.25,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.45,10.915765464615385,12.381530929230768,13.847296393846154,15.313061858461538,16.778827323076925,18.24459278769231,19.710358252307692,21.17612371692308,22.641889181538463,24.107654646153847,25.57342011076923,27.039185575384618,{"y":28.50495104,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.45,10.038690048,10.627380096,11.216070144,11.804760192,12.39345024,12.982140287999998,13.570830335999998,14.159520383999999,14.748210431999999,15.336900479999999,15.925590527999997,16.514280575999997,{"y":17.102970623999997,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.45,8.99716299076923,8.544325981538462,8.091488972307692,7.6386519630769225,7.185814953846154,6.732977944615385,6.280140935384615,5.827303926153846,5.374466916923077,4.921629907692308,4.468792898461539,4.01595588923077,{"y":3.56311888,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€28.50Average Price Target€17.10Lowest Price Target€3.56
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:XRP2
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
€66.81→€17.82
Hold
56.28%
Upside
Downgraded
10/21/26
Silence Therapeutics downgraded to Neutral from Buy at H.C. WainwrightSilence Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
William Blair Analyst forecast on DE:XRP2
Myles Minter
William Blair
William Blair
―
Hold
―
Downgraded
10/19/26
Silence Therapeutics downgraded to Market Perform from Outperform at William BlairSilence Therapeutics downgraded to Market Perform from Outperform at William Blair
Jefferies Analyst forecast on DE:XRP2
Andrew Tsai
Jefferies
Jefferies
€31.18→€17.82
Hold
56.28%
Upside
Downgraded
10/19/26
Silence Therapeutics downgraded to Hold from Buy at JefferiesSilence Therapeutics downgraded to Hold from Buy at Jefferies
Chardan Capital Analyst forecast on DE:XRP2
Keay Nakae
Chardan Capital
Chardan Capital
€24.05→€17.82
Hold
56.28%
Upside
Downgraded
10/19/26
Silence Therapeutics downgraded to Neutral from Buy at ChardanSilence Therapeutics downgraded to Neutral from Buy at Chardan
Morgan Stanley Analyst forecast on DE:XRP2
Michael Ulz
Morgan Stanley
Morgan Stanley
€22.27→€28.5
Buy
150.04%
Upside
Assigned
08/11/26
Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley
Goldman Sachs Analyst forecast on DE:XRP2
Richard Law CFA
Goldman Sachs
Goldman Sachs
€3.56
Sell
-68.74%
Downside
Reiterated
07/27/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vericel (NASDAQ: VCEL) and Silence Therapeutics (NASDAQ: SLN)
Cantor Fitzgerald Analyst forecast on DE:XRP2
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
06/24/26
Silence Therapeutics initiated with an Overweight at Cantor FitzgeraldSilence Therapeutics initiated with an Overweight at Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:XRP2
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
€66.81→€17.82
Hold
56.28%
Upside
Downgraded
10/21/26
Silence Therapeutics downgraded to Neutral from Buy at H.C. WainwrightSilence Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
William Blair Analyst forecast on DE:XRP2
Myles Minter
William Blair
William Blair
―
Hold
―
Downgraded
10/19/26
Silence Therapeutics downgraded to Market Perform from Outperform at William BlairSilence Therapeutics downgraded to Market Perform from Outperform at William Blair
Jefferies Analyst forecast on DE:XRP2
Andrew Tsai
Jefferies
Jefferies
€31.18→€17.82
Hold
56.28%
Upside
Downgraded
10/19/26
Silence Therapeutics downgraded to Hold from Buy at JefferiesSilence Therapeutics downgraded to Hold from Buy at Jefferies
Chardan Capital Analyst forecast on DE:XRP2
Keay Nakae
Chardan Capital
Chardan Capital
€24.05→€17.82
Hold
56.28%
Upside
Downgraded
10/19/26
Silence Therapeutics downgraded to Neutral from Buy at ChardanSilence Therapeutics downgraded to Neutral from Buy at Chardan
Morgan Stanley Analyst forecast on DE:XRP2
Michael Ulz
Morgan Stanley
Morgan Stanley
€22.27→€28.5
Buy
150.04%
Upside
Assigned
08/11/26
Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley
Goldman Sachs Analyst forecast on DE:XRP2
Richard Law CFA
Goldman Sachs
Goldman Sachs
€3.56
Sell
-68.74%
Downside
Reiterated
07/27/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vericel (NASDAQ: VCEL) and Silence Therapeutics (NASDAQ: SLN)
Cantor Fitzgerald Analyst forecast on DE:XRP2
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
06/24/26
Silence Therapeutics initiated with an Overweight at Cantor FitzgeraldSilence Therapeutics initiated with an Overweight at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
SIBNSI-Bone
IMUXImmunic
MDWDMediwound
HROWHarrow Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Silence Therapeutics

3 Months
Michael UlzMorgan Stanley
Success Rate
10/20 ratings generated profit
50%
Average Return
+9.93%
Copying Michael Ulz's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +9.93% per trade.
1 Year
Michael UlzMorgan Stanley
Success Rate
12/20 ratings generated profit
60%
Average Return
+67.31%
Copying Michael Ulz's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +67.31% per trade.
2 Years
Michael UlzMorgan Stanley
Success Rate
12/20 ratings generated profit
60%
Average Return
+88.06%
Copying Michael Ulz's trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +88.06% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XRP2 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
10
8
6
4
4
Buy
3
3
4
3
3
Hold
0
0
0
0
4
Sell
0
0
0
0
0
Strong Sell
0
1
1
1
0
total
13
12
11
8
11
In the current month, XRP2 has received 7 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. XRP2 average Analyst price target in the past 3 months is 17.10.
Each month's total comprises the sum of three months' worth of ratings.

XRP2 Financial Forecast

XRP2 Earnings Forecast

Next quarter’s earnings estimate for XRP2 is -€0.10 with a range of -€0.25 to -€0.06. The previous quarter’s EPS was -€0.08. XRP2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year XRP2 has Performed in-line its overall industry.
Next quarter’s earnings estimate for XRP2 is -€0.10 with a range of -€0.25 to -€0.06. The previous quarter’s EPS was -€0.08. XRP2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year XRP2 has Performed in-line its overall industry.

XRP2 Sales Forecast

Next quarter’s sales forecast for XRP2 is €110.40K with a range of €0.00 to €356.14K. The previous quarter’s sales results were €0.00. XRP2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year XRP2 has Performed in-line its overall industry.
Next quarter’s sales forecast for XRP2 is €110.40K with a range of €0.00 to €356.14K. The previous quarter’s sales results were €0.00. XRP2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year XRP2 has Performed in-line its overall industry.

XRP2 Stock Forecast FAQ

What is DE:XRP2’s average 12-month price target, according to analysts?
Based on analyst ratings, Silence Therapeutics’s 12-month average price target is 17.10.
    What is DE:XRP2’s upside potential, based on the analysts’ average price target?
    Silence Therapeutics has 50.03% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Silence Therapeutics a Buy, Sell or Hold?
          Silence Therapeutics has a consensus rating of Hold, which is based on 1 buy ratings, 4 hold ratings and 1 sell ratings.
            What is Silence Therapeutics’s share price target?
            The average share price target for Silence Therapeutics is 17.10. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €28.50 ,and the lowest forecast is €3.56. The average share price target represents 50.03% Increase from the current price of €11.4.
              What do analysts say about Silence Therapeutics?
              Silence Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Silence Therapeutics?
                To buy shares of DE:XRP2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.